Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
暂无分享，去创建一个
K. Reddy | T. Hassanein | D. Dieterich | H. Mo | K. Kowdley | D. Bernstein | D. Nelson | M. Rodríguez-Torres | N. Afdhal | M. Sulkowski | I. Jacobson | R. Hindes | E. Lawitz | R. Hyland | J. Lalezari | E. Dejesus | F. Poordad | W. Symonds | A. Sheikh | A. Muir | D. Jensen | B. Freilich | Ming-hua Lin | G. Abrams | N. Bzowej | E. Albanis | M. Berrey | J. Darling | M. Mader | M. Rodríguez-Torres | M. Lin | Douglas T. Dieterich | Kris V Kowdley | David R. Nelson | K. R. Reddy | Gary A Abrams | Jay P Lalezari | David E Bernstein | Ming-hua Lin | Jacob Lalezari